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P38α/JNK signaling restrains erythropoiesis by
suppressing Ezh2-mediated epigenetic silencing
of Bim
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Marie-Dominique Filippi5, Hal E. Broxmeyer6 & Reuben Kapur1
While erythropoietin (EPO) constitutes the major treatment for anemia, a range of anemic
disorders remain resistant to EPO treatment. The need for alternative therapeutic strategies
requires the identification of mechanisms that physiologically restrain erythropoiesis. Here
we show that P38α restrains erythropoiesis in mouse and human erythroblasts independently
of EPO by integrating apoptotic signals during recovery from anemia. P38α deficiency pro-
motes JNK activation through increased expression of Map3k4 via a negative feedback
mechanism. JNK prevents Cdk1-mediated phosphorylation and subsequent degradation by
Smurf2 of the epigenetic silencer Ezh2. Stabilized Ezh2 silences Bim expression and protects
erythroblasts from apoptosis. Thus, we identify P38α/JNK signaling as a molecular brake
modulating erythropoiesis through epigenetic silencing of Bim. We propose that inhibition of
P38α, by enhancing erythropoiesis in an EPO-independent fashion, may provide an alter-
native strategy for the treatment of anemia.
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A remarkable feature of erythropoiesis is the coordinationof proliferation, differentiation, and apoptosis of erythroidcells to precisely achieve erythropoietic homeostasis to
avoid anemia and polycythemia1. Anemia is a common disease
arising from various causes, including Myelodysplastic syn-
dromes, thalassemia, cancer chemotherapy, chronic kidney dis-
ease, and hemorrhage2. The pro-erythropoietic factor
erythropoietin (EPO) is often employed for anemia therapy.
However, questions have been raised about the safety of EPO
given its potential for tumor promotion in cancer-related ane-
mia3. Moreover, many acute and chronic anemias, including
hemolysis, sepsis, and genetic bone marrow failure diseases such
as Diamond-Blackfan anemia are untreatable with EPO4. To
overcome these hurdles, new molecular mechanisms need to be
identified that physiologically restrain erythropoiesis by acting as
molecular brakes to prevent over-active erythropoiesis caused by
pro-erythropoietic signals. Inhibiting these restraining mechan-
isms could provide alternative approaches to treat anemia in an
EPO-independent fashion.
P38 MAPK (Mitogen-activated protein kinase) is an important
pathway involved in diverse biological processes. P38 modulates
cell proliferation, controls cell survival and decides cell fate during
differentiation. P38 pathway functions mainly by phosphorylating
and activating important transcription factors in response to
different stimuli, including ATF2, CREB, and MEF25. There are
four members within the P38 MAPK family, including P38α,
P38β, P38γ, and P38δ. These members are encoded by different
genes and have different tissue expression patterns. Among them,
P38α is ubiquitously expressed. P38α modulates the function of
different cell types6. There are two distinct developmental defects
reported in global P38α knockout mice by two separate groups
using different mouse strains. One displayed embryonic death
with highly anemic appearance due to reduced EPO production
and another showed even earlier embryonic lethality due to
placental developmental defects7,8. In a P38α conditional mice
model in which Cre recombinase was expressed in the whole-
mouse embryo but not in the placenta by crossing to MORE-Cre
mice, no anemia or EPO defects were observed9. However, the
intrinsic and cell autonomous role of P38α in adult steady-state or
stressful erythropoiesis has not been established. Loss of P38α
causes activation of JNK in the liver9. P38 inhibitors are in clinical
trials and have the potential for the treatment of human disease.
Therefore, it is important to understand the downstream targets
and functional outcomes induced by P38α deficiency.
Using primary human erythroblasts derived from human
CD34+ hematopoietic stem and progenitor cells (HSPCs) and
P38α conditional knockout mice, we find that P38α acts as a
molecular brake during anemia recovery through integrating
apoptotic signals and by shortening the lifespan of erythroblasts
to prevent potential over-active erythropoiesis caused by pro-
erythropoietic signaling. Loss of P38α in erythroblasts activates
JNK through augmented Map3k4 via a negative feedback circuit
revealed by gene expression profiling. Functionally, JNK serves as
a pro-survival signal independent of EPO by compromising Bim
expression via stabilizing the epigenetic silencer Ezh2 in ery-
throblasts. JNK-controlled Cdk1 activity modulates full interac-
tion of Ezh2 to the E3 ligase Smurf2 through multiple threonine
phosphorylation sites within Ezh2. Our findings identify a key
signaling cascade involving P38α/JNK/Cdk1/smurf2/Ezh2/Bim in
fine tuning stress erythropoiesis.
Results
Self-restraint role of P38 in stress erythropoiesis. Human CD34
+ HSPCs were induced to undergo erythroid differentiation after
stimulation with pro-erythropoietic factors erythropoietin (EPO)
and stem cell factor (SCF), this provides a valuable tool to study
human erythropoiesis in vitro10,11. The developmental char-
acteristics of CD34+ HSPCs-derived erythroblasts were evaluated
by examining the expression of cell surface markers CD71 and
CD235a and by cell morphology (Supplementary Fig. 1a). We
detected a more enduring and sustained activation of P38 in those
cells stimulated by EPO than by SCF, suggesting a physiologic
role for P38 in erythropoiesis (Fig. 1a and Supplementary Fig. 1b).
To address the role of P38 in regulating erythroblasts, we found
that SB203580, a specific inhibitor of P38, which inhibited the
phosphorylation of ATF2 (a well-known P38 target), did not alter
erythroid differentiation of HSPCs (Supplementary Fig. 1c, d).
Cell cycle distribution was similar between control and P38-
inhibited human erythroblasts using ki67 staining12 (Supple-
mentary Fig. 1e). Given the association between elevated P38
activity and stress-induced apoptosis, we assessed whether sup-
pression of P38 activity protected erythroblasts from oxidative
stress or chemotherapy-triggered cell death, which is often
observed in anemic patients. Buthionine sulfoximine (BSO)
causes oxidative stress by depleting intracellular glutathione.
Inhibition of P38 markedly elevated resistance of human ery-
throblasts to BSO-induced cell death without disturbing the cell
cycle (Fig. 1b and Supplementary Fig. 1f). Inhibition of P38 also
notably reduced cisplatin-induced apoptosis of human erythro-
blasts with no profound effects on cell cycle status (Supplemen-
tary Fig. 1g, h). We predicted that pro-survival signaling
downstream of EPO and SCF would compromise pro-apoptosis
P38 signaling in human erythroblasts under normal conditions.
As expected, inhibition of Jak2, which inhibited the phosphor-
ylation of stat5 (a well-known Jak2 target), uncovered the pro-
apoptotic function of P38 (Fig. 1c and Supplementary Fig. 1i, j).
Therefore, our finding that pro-apoptosis P38 pathway is acti-
vated by pro-erythropoietic signals such as EPO and SCF indicate
that P38 potentially performs an intrinsic restraining function to
limit over-active erythropoiesis by integrating apoptotic signals.
To further explore the role of P38 in erythropoiesis in vivo, we
generated a conditional knockout mouse model in which P38α
was deleted in hematopoietic cells by crossing P38αflox/flox mice
with Mx-Cre mice6,13. P38α locus was excised and P38α protein
was completely abolished in sorted erythroblasts from P38α−/−
mice after poly IC injections compared to littermate controls
(P38α+/− mice) (Supplementary Fig. 2a). In steady-state
erythropoiesis, loss of P38α showed normal peripheral blood
erythroid parameters, including hematocrits (HCT) and RBC
counts (Fig. 1d, 0 time point). Differentiation of mouse
erythroblasts can be monitored by assessing the expression
different cell surface proteins14,15. We next examined erythroblast
differentiation characteristics by monitoring cell surface expres-
sion of CD71 and Ter119 combined with forward scatter (FSC)
using flow cytometry14. A modest increase in pro-erythroblasts
(Pro-E) associated with reduced apoptosis was observed in P38α
−/− bone marrow (BM) cells relative to controls; whereas, the
frequency, viability and proliferation of basophilic erythroblasts
(Ery-A), late basophilic and polychromatic erythroblasts (Ery-B)
and orthochromatic erythroblasts (Ery-C) was comparable
between P38α+/− and P38α−/− mice (Supplementary Fig. 2b–
d). No obvious difference was observed in the composition of
splenic erythroblast subsets (Supplementary Fig. 2e–g). These
results demonstrate that P38α may modulate survival of early
erythroblasts in BM under steady-state conditions, but loss of
P38α is not sufficient to perturb erythropoietic homeostasis.
To investigate whether P38α modulates the response to
anemia, we subjected P38α+/− and P38α−/− mice to phenylhy-
drazine (PHZ) treatment to induce hemolytic anemia. In
response to PHZ challenge, P38α−/− mice showed accelerated
recovery of HCTs and RBC counts in peripheral blood compared
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to P38α+/− mice (Fig. 1d). To further evaluate cell autonomous
role of P38α in stress erythropoiesis, we transplanted BM cells
from P38α+/− and P38α−/− mice into lethally irradiated recipient
C57BL/6-CD45.1 mice. After donor chimerism stabilized (~90%),
transplanted mice were subjected to PHZ challenge. An
accelerated erythropoietic recovery from anemia was observed
in recipient mice transplanted with P38α−/− BMs, suggesting the
function of P38α in stress erythropoiesis is cell intrinsic
(Supplementary Fig 3a and Fig. 1e).
EPO concentration in the serum and expression of EPOR and
TFR2 in erythroblasts was comparable between P38α+/− and
P38α−/− mice after PHZ challenge, (Fig. 1f, g). During recovery
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from anemia, a significant increase in phosphorylated P38 was
unexpectedly observed in erythroblasts (Fig. 1h) and P38α−/−
mice exhibited increase in the number of Pro-E, Ery-A and Ery-B
cells in the BM and in the spleen compared to controls (Fig. 1i
and Supplementary Fig. 3b). Although the frequency of Pro-E,
Ery-A, and Ery-B was greater in P38α−/− BM compared to
P38α+/− BM, the frequency of Ery-A, Ery-B, and Ery-C within
the Ter119+ population was comparable between P38α+/− and
P38α−/− mice, suggesting P38α may not be involved in
modulating the differentiation of these subsets during stress
erythropoiesis (Fig. 1i). PHZ-challenged mice showed enhanced
cell cycle progression in erythroblasts in both P38α+/− and
P38α−/− mice, demonstrating similar compensatory proliferation
in erythroblasts during anemia recovery (Supplementary Fig. 3c,
d). However, deletion of P38α led to reduced apoptosis in Pro-E,
Ery-A, and Ery-B subsets both in the BM and in the spleen during
recovery from anemia (Fig. 1j and Supplementary Fig. 3e).
Administration of SB203580 also prevents apoptosis of BM
erythroblasts without affecting cell cycle distribution in PHZ-
challenged wild-type mice (Fig. 1k and Supplementary Fig. 3f).
These results suggest that P38 integrates apoptotic cues in
erythroblasts during the recovery from anemia to potentially limit
over-active erythropoiesis.
Next, we challenged the mice with 5-fluorouracil (5-FU)
(Supplementary Fig. 4a). During the recovery of this central
anemia model, which induces anemia by depletion of proliferat-
ing progenitor cells, an enhanced P38 activity was observed
(Supplementary Fig. 4b) and P38α−/− mice exhibited accelerated
erythropoietic recovery (Supplementary Fig. 4c), associated with
increase in the numbers of Pro-E, Ery-A, and Ery-B and reduced
apoptosis relative to P38α+/− mice (Supplementary Fig. 4d, e).
Thus, activation of P38 represents a physiologic molecular brake
during the recovery phase of anemia by regulating erythroblast
apoptosis; suppression of P38 activity relieves this restriction and
promotes stress erythropoiesis.
Loss-of-P38α drives JNK activation via augmented Map3k4. To
understand how P38α deficiency exerts a pro-survival function in
erythroblasts, we performed gene expression profiling in P38α+/−
versus P38α−/− BM erythroblasts during the recovery of anemia
in response to PHZ challenge. A total of 1086 genes were iden-
tified to be differentially expressed (DE) between P38α−/− and
P38α+/− erythroblasts (q-value ≤0.05; fold change ≥2). Ingenuity
pathway analysis (IPA) revealed “cell death and survival” as the
most enriched molecular and cellular functional category from
DE genes (q-value ≤0.05; fold change ≥1.5) (Supplementary
Fig. 5a). Gene set enrichment analysis (GSEA) identified enriched
Molecular Signature database gene sets in P38α−/− erythroblasts,
including suppression in the “inflammatory response pathway”
(Supplementary Fig. 5b). Consistently, we detected reduced
expression of TNF-α in P38α−/− erythroblasts compared with
P38α+/− erythroblasts (Supplementary Fig. 5c).
Gene expression analysis revealed elevated expression of JunD,
a downstream target of JNK, in P38α−/− erythroblasts. We
wondered whether JNK is activated in erythroblasts in response
to loss of P38α as reported in liver9. P38α−/− erythroblasts
showed similar JNK activation under steady-state and stress
conditions compared to P38α+/− erythroblasts (Fig. 2a). Unex-
pectedly, GSEA revealed upregulation of the “P38 MKK3/6
pathway” in P38α−/− erythroblasts, implying that a negative
feedback circuit may occur in P38α−/− erythroblasts in order to
restore P38α signaling (Fig. 2b, c). q-PCR confirmed enhanced
expression of MKK6, MKK3, and GADD45g (Fig. 2d), two direct
upstream kinases and a protein responsible for promoting P38
activation5,16, but not MKK4 and MKK7, the direct upstream
kinases of JNK, in P38α−/− erythroblasts (Supplementary Fig. 5d).
Enhanced expression of other P38 upstream kinases like Tao
kinase 317 and RIPK118 were also noted in our gene expression
profile (Fig. 2c). Remarkably, gene expression profiling also
revealed upregulation in the expression of Map3k4 and Map3k10,
which are upstream kinases of MKKs and mediate activation of
P3819,20, in P38α−/− erythroblasts (Fig. 2c). Increased Map3k4
expression was confirmed in P38α−/− erythroblasts, whereas
expression of Map3k11 was unaltered, with Map3k10 mRNA
level too low to detect (Fig. 2d, e). These findings highlight the
importance of P38α in stress erythropoiesis and demonstrate that
negative feedback-induced augmentation of the upstream kinase
of P38α is not limited to MKKs but acts upstream to the level of
Mapkkks, in an attempt to restore P38α signaling.
An important feature of Map3k4 is to activate both P38 and
JNK20. We reasoned that enhanced Map3k4 expression in
P38α−/− cells exclusively activates JNK due to lack of competition
from P38α. Interestingly, elevated GADD45g can collaborate with
Map3k416,21. As expected, silencing Map3k4 by delivering a
retrovirus containing shRNA against Map3k4 into P38α−/− and
P38α+/− cells effectively ablated P38α deficiency-induced activa-
tion of JNK (Supplementary Fig. 5e and Fig. 2f). In human
erythroblasts, inhibition of P38 by SB203580 activated JNK and
this was associated with elevated expression of Map3k4 (Fig. 2g).
This reveals a conserved mechanism in mice and humans which
involves rewiring of JNK activation in the absence of P38α
(Fig. 2h).
JNK signaling protects erythroblasts independent of EPO.
Since loss of Map3k4 leads to apoptosis in certain tissues20 and
JNK activity supports the survival of acute myeloid leukemia
cells22, we questioned if JNK plays a role in modulating erythro-
blast function. We first examined whether JNK can be activated by
EPO in human erythroblasts. Unlike P38, a relatively high basal
JNK activity was observed in human erythroblasts, and EPO
Fig. 1 Self-restraint role of P38 in stress erythropoiesis. a Phosphorylation of P38 in starved human CD34+ HSPCs-derived erythroblasts stimulated with
EPO (2 Uml−1) at indicated time points. b, c Apoptosis in human CD34+ HSPCs-derived erythroblasts induced by BSO (200 nM) (n= 4) (b) or Jak2
inhibitor II (40 µM) (n= 3) (c) with DMSO or SB203580 (10 µM) quantified by flow cytometry using Annexin V and DAPI staining. d PHZ-induced anemia
and recovery in P38α+/− and P38α−/− mice. Analysis of Hematocrits (left) and RBC counts (right) were shown (n= 7). e Lethally irradiated C57BL/6-
CD45.1 recipient mice were transplanted with bone marrow cells from P38α+/− and P38α−/−mice. Chimeric mice were challenged with PHZ and HCT and
RBC counts were assessed (n= 5). f, g EPO serum concentration was measured by ELISA in P38α+/− and P38α−/− mice treated with vehicle (n= 4) or
PHZ (n= 5) (f) and mRNA levels of EPOR and TFR2 (g) in PHZ-challenged P38α+/− and P38α−/− mice. h–j During recovery (day 4) from PHZ-induced
anemia in P38α+/− and P38α−/−mice, western blot (left) and densitometry analysis (right) of phospho-P38 in BM erythroblasts. Data are shown as mean
± s.e.m from three separate experiments (h). Representative flow cytometry plot (left), numbers and percentages of BM erythroblast subsets (middle), and
frequencies of Ery-A, Ery-B, and Ery-C within Ter119+ population (right) (n= 7) (i). Representative flow cytometry profile (left) and quantification (right) of
BM erythroblast subsets undergoing apoptosis in P38α+/− (n= 6) and P38α−/− mice (n= 5) (j). k Mice were injected intraperitoneally with either
SB203580 (15mg per kg body weight) or vehicle every other day before and during PHZ challenge and BM apoptotic erythroblast subsets were measured
as in j (n= 4). Blots are representative of three independent experiments. Data are shown as mean ± s.e.m. *P < 0.05 (two-tailed unpaired Student’s t-test)
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stimulation resulted in moderate and transient JNK activation,
suggesting a limited role for EPO in maintaining JNK activity
(Fig. 3a). Surprisingly, SP600125, a JNK kinase inhibitor, was
sufficient to trigger apoptosis in human erythroblasts (Fig. 3b). We
also observed apoptosis in human erythroleukemic TF1 cells in the
presence of a JNK inhibitor (Supplementary Fig. 5f). Since
TF1 cells do not rely on EPO for growth, the requirement for JNK
activity for their survival suggests that JNK acts as a safeguard in
the erythroid lineage independent of EPO. Consistent with the
pharmacological results, silencing JNK1 by introducing a shRNA
against JNK1 into human erythroblasts induced cell death (Sup-
plementary Fig. 5g–i and Fig. 3c). Although both small molecule
inhibitors and shRNA knockdown have off-target effects, com-
bined results from mouse models, shRNA knockdown, and small
molecule inhibitors might mitigate concerns associated with
possible off-target effects to a large extent.
Since activated JNK contributed to the enhanced survival seen
in P38α−/− mouse erythroblasts similar to human erythroblasts,
we predicted that P38α−/− erythroblasts would be more
vulnerable to JNK inhibition. Indeed, SP600125 administration
in P38α−/− mice resulted in an early and more severe decline in
HCTs and RBCs, and reduction in the numbers of BM Pro-E,
Ery-A, and Ery-B subsets, which was accompanied by enhanced
apoptosis (Supplementary Fig. 5j and Fig. 3d, e). The fact that
dependence on high JNK activity sensitizes P38α−/− mice to JNK
inhibition-induced anemia through increased apoptosis of
erythroblasts further demonstrates that the JNK pathway acts as
a pro-survival signal in erythroblasts.
JunD transduces pro-survival signals downstream of JNK23.
Elevated expression of JunD mRNA and protein were observed in
P38α−/− erythroblasts with high JNK activity compared to
P38α+/− erythroblasts (Fig. 3f, g). In human erythroblasts,
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loss of P38α rewires increased Map3k4 to exclusively activate JNK. Blots are representative of three independent experiments. Data are shown as mean ±
s.e.m. *P < 0.05 (two-tailed unpaired Student’s t-test)
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inhibition of JNK substantially ablated expression of JunD
(Fig. 3h). Functionally, knockdown of JunD resulted in apoptosis
of human erythroblasts more moderately than JNK1 silencing
(Supplementary Fig. 5k and Fig. 3i), suggesting there might be
other targets of JNK, in addition to JunD, involved in protecting
erythroblasts.
JNK protects erythroblasts by compromising Bim expression.
Since the tumor suppressor P53 is a master regulator of apoptosis
in many cell types, including erythroblasts24, and mutations in
the ribosomal protein genes cause erythroid cell death in patients
with Diamond-Blackfan anemia via P53 activation11, we exam-
ined whether P53 is involved in JNK inhibition-induced apoptosis
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in human erythroblasts. We evaluated the impact of JNK inhi-
bition on expression of P53, and surprisingly found that protein
levels of P53 and Noxa, a well-known P53 target, were markedly
reduced upon inhibition of JNK in human erythroblasts (Fig. 4a).
Cycloheximide (CHX)-chase assay revealed that JNK inactivation
triggers accelerated degradation of P53 compared to con-
trols (Fig. 4b), suggesting that JNK activity is essential for
maintaining stability of P53 in human erythroblasts.
Moreover, P38α−/− erythroblasts, with high JNK activity,
exhibited increased expression of P53 protein, but not P53
mRNA, compared to P38α+/− erythroblasts (Fig. 4c). This is
consistent with GSEA analysis that displayed enhanced enrich-
ment of the P53 pathway in P38α−/− erythroblasts (Fig. 4d).
These data suggest that P38α is a physiological negative regulator
of P53 via JNK and that P53 might not contribute to JNK
inhibition-induced apoptosis in erythroblasts.
To address whether cell death receptor pathways which play a
critical role in controlling erythroblast survival are downstream
targets of JNK and responsible for mediating erythroblast cell
death, we performed q-PCR analysis. As seen in Supplementary
Fig. 6a, JNK inactivation did not significantly alter the expression
of Fas, DR3, and DR4 but decreased the expression of FasL. Bcl-2
family proteins play a central role in regulating erythroblast cell
death25,26. Among the Bcl-2 family members, we found the
expression of Bim, but not bcl-Xl, Mcl-1, and Bik, to be
significantly elevated by SP600125 (Fig. 4e and Supplementary
Fig. 6b). Knockdown of JNK1 by shRNA also activated Bim
expression in these cells (Fig. 4f). Importantly, knockdown of Bim
by lentivirus carrying Bim-specific shRNA enabled erythroblasts
to resist JNK inactivation-induced cell death (Supplementary
Fig. 6c and Fig. 4g). Thus, the JNK pathway supports the survival
of erythroblasts by regulating the expression of Bim.
Smurf2-mediated degradation of Ezh2 triggers Bim expression.
Elevated Bim mRNA levels imply that JNK perhaps modulates
Bim transcription. Therefore, we focused on transcription factors
Foxo3a and LRF, both of which are involved in regulating Bim
expression and erythropoiesis25,27. Phosphorylation of Foxo3a
inhibits its function28. We found Foxo3a phosphorylation to be
unaltered in response to SP600125. Expression of LRF protein
remained unchanged by JNK inactivation (Supplementary
Fig. 7a). These results suggest that both Foxo3a and LRF might
not be involved in regulating JNK-mediated Bim expression. This
prompted us to seek alternative targets.
Ezh2, a component of the polycomb repressive complex 2
(PRC2), has been reported to negatively regulate Bim
expression29,30. Ezh2 regulates erythropoiesis31,32. We wondered
whether Ezh2 is a downstream target of JNK in regulating Bim
expression. In human erythroblasts, Ezh2 mRNA levels were
modestly elevated, whereas Ezh2 protein was markedly reduced
upon inhibiting the activity of JNK (Fig. 5a). Silencing JNK1 also
significantly attenuated Ezh2 expression (Fig. 5b). Cycloheximide
chase assay performed in human erythroblasts revealed that
inactivation of JNK notably accelerated degradation of Ezh2
protein, suggesting that JNK might control Ezh2 protein stability
(Fig. 5c). Importantly, degradation of Ezh2 by JNK inactivation
could be blocked by proteasome inhibitor MG132, suggesting the
involvement of the ubiquitin-proteasome pathway in Ezh2
regulation (Fig. 5d). Consistently, elevated HOXA9 mRNA level,
a well-known target of PRC2, was observed in human
erythroblasts when JNK activity was compromised by SP600125
or by JNK1 silencing (Fig. 5e). In agreement with these results, we
found reduced binding of Ezh2 and H3K27 trimethylation on the
Bim promoter, as measured by a quantitative chromatin
immunoprecipitation assay (Fig. 5f).
We then tested the role of Ezh2 in modulating erythroblast
survival. In human erythroblasts, GSK126, an Ezh2 inhibitor,
induced Bim expression while compromising global H3K27me3
and initiated cell death in a concentration dependent manner
(Fig. 5g, h and Supplementary Fig. 7b). Similar results were
observed when Ezh2 was silenced by shRNA (Supplementary
Fig. 7c and Fig. 5i, j). Ezh2 activity was also required for the
survival of TF1 cells (Supplementary Fig. 7d). These results
indicate that Ezh2 is required for protecting human erythroblasts
by inducing epigenetic silencing at Bim locus. In accordance with
findings in human erythroblasts, P38α−/− erythroblasts, which
show increased JNK activation, also displayed elevated Ezh2
protein compared with controls (Fig. 5k). Consistently, reduced
expression of HOXA9 was observed in P38α−/− erythroblasts
compared to P38α+/− erythroblasts (Fig. 5l). Moreover, P38α−/−
erythroblasts showed greater sensitivity to Ezh2 inhibition-
induced apoptosis than P38+/− erythroblasts, suggesting depen-
dence of P38α−/− erythroblasts on higher level of Ezh2 (Fig. 5m).
Together, our findings demonstrate that Ezh2 is a target of the
P38α/JNK pathway and is required for protecting erythroblasts by
silencing Bim expression. Thus, our results link Ezh2, a major
epigenetic regulator of gene expression, to major MAPK signaling
pathway to define a mechanism for maintenance of erythropoietic
homeostasis.
Smurf2, a ubiquitin E3 ligase, can degrade Ezh233. To
investigate the role of smurf2 in JNK-mediated Ezh2 protein
stability in human erythroblasts, we silenced smurf2 by delivering
lentivirus containing shRNA against smurf2 into human
erythroblasts. This treatment enhanced the expression of Ezh2
under steady-state and JNK inactivation conditions compared to
control shRNA and compromised the expression of Bim upon
JNK inactivation (Supplementary Fig. 7e and Fig. 5n). Impor-
tantly, erythroblasts lacking Smurf2 showed enhanced resistance
to apoptosis in response to JNK inhibition (Fig. 5o). These results
support a key signaling cascade involving JNK/Smurf2/Ezh2 in
regulating survival of erythroblasts.
Cdk1 phosphorylates Ezh2 to mediate its binding to Smurf2.
To further explore the mechanisms underlying Ezh2 regulation
by Smurf2, we mapped the binding domain between Ezh2 and
Smurf2. Smurf2 contains an N-terminal C2 domain and a C-
terminal HECT domain which has E3 ligase activity with three
WW domains in the middle34. Co-immunoprecipitation showed
Fig. 3 JNK promotes survival of erythroblasts independent of EPO. a Phosphorylation of JNK in starved human erythroblasts stimulated with EPO (2 Uml
−1) at indicated time points. b Representative flow cytometry profile (left) and quantification (right) of apoptotic human erythroblasts induced by
SP600125 (20 µM) for 36 h (n= 5). c Representative flow cytometry plots (left) and quantification (right) of apoptotic human erythroblasts by JNK1-
specific shRNA (n= 4). d HCT and RBC counts on day 0 (n= 8) and on indicated time points (n= 5) in P38α+/− and P38α−/−mice treated with vehicle or
SP600125. e Number (n= 4) and apoptosis (n= 5) of erythroblast subsets at fourth week in P38α+/− and P38α−/− mice exposed to vehicle or SP600125.
f, g mRNA (f) and protein (g) expression of JunD from sorted P38α+/− and P38α−/− erythroblasts during recovery (day 4) from PHZ-induced anemia.
h JunD protein levels in SP600125 (20 µM) treated human erythroblasts by immunoblotting. i Representative flow cytometry profile (left) and
quantification (right) of apoptotic human erythroblasts induced by JunD-specific shRNA (n= 4). Blots are representative of three independent
experiments. Data are shown as mean ± s.e.m. *P < 0.05 (two-tailed unpaired Student’s t-test)
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strong interaction between full-length Ezh2 and the HECT
domain of Smurf2, but not the C2 or WW domains (Fig. 6a).
Next, we mapped the region within Ezh2 that mediates interac-
tion with the HECT domain of Smurf2. We designed a series of
Ezh2 truncated constructs, including an N-terminal fragment
(amino acid residues 1–348), referred to as Ezh2-N, middle
region amino acid residues 330–530 which consist of multiple
threonine phosphorylation sites referred to as Ezh2-M and a C-
terminal domain containing amino acid residues 523–751 refer-
red to as Ezh2-C. We observed strong binding of the HECT
domain to the Ezh2-M fragment (Fig. 6b). These results
demonstrate that the middle region of Ezh2 interacts with the C-
terminal HECT domain of Smurf2.
There are four threonine phosphorylation sites within Ezh2-M,
including Ter350, Ter372, Ter419, and Ter492. Three of them
have been reported to be phosphorylated by Cdk1/2, and two of
them (T350 and T492) regulate Ezh2 stability35–38. Although a
previous report showed that T372 can be phosphorylated by
P3839, motif analysis strongly predicts T372 as a CDK consensus
site40. To this end, we generated one quadruple-point mutant
with four threonine residues mutated to alanine (A) (referred to
as Ezh2-M 4A), and one triple-point mutant with a T372 residue
remaining intact (referred to as Ezh2-M 3A372T). Immunopre-
cipitation showed enhanced phosphorylation of the 3A372T
mutant as revealed by a phosphorylated CDK substrate antibody
(pT-P Ab) compared to a 4A mutant. Notably, Roscovitine, a
CDK inhibitor, significantly ablated the phosphorylation of
3A372T mutant (Supplementary Fig. 8a). In support of this, co-
expression of cdk1 and cyclin B significantly increased phosphor-
ylation of the Ezh2-M 3A372T mutant, but not of the Ezh2-M 4A
mutant (Supplementary Fig. 8b). These findings demonstrate that
T372 can be phosphorylated by cdk1.
Since we noticed that Lysine-42133, which is critical for
smurf2-mediated Ezh2 degradation, is surrounded by four
threonine sites, we assessed if phosphorylation of these threonine
sites mediates the interaction between Ezh2 and smurf2. Wild
type (Ezh2-M) and a series of Ezh2 mutants including a
quadruple threonine mutant (Ezh2-M 4A), two double threonine
mutants (Ezh2-M T350A/T492A and Ezh2-M T372A/T419A)
were co-expressed with the HECT domain of smurf2.
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Co-immunoprecipitation showed that the double threonine
mutation in Ezh2-M significantly weakened the binding,
compared to wild type, and the quadruple threonine mutation
abolished the interaction completely (Fig. 6c). In support of these
findings, in vivo ubiquitination assay showed Smurf2 caused
dramatically reduced poly-ubiquitination of the 4A mutant of
Ezh2 compared to wild-type Ezh2 (Fig. 6d). To further address
the functional significance of the threonine phosphorylation sites
in Ezh2, we overexpressed the full length wild type or 4A mutant
of Ezh2 in TF1 cells. Compared to wild type, the 4A mutant of
Ezh2 displayed enhanced stability in a CHX chase assay and
showed resistance to degradation induced by JNK inactivation
(Fig. 6e, f). It has been proposed that individual threonine sites
may have distinct impact on Ezh2 activity35,36. Expression of the
Ezh2 4A mutant significantly increased global H3K27 trimethyla-
tion compared with wild-type Ezh2 in sorted GFP+ TF1 cells
(Fig. 6g). Importantly, expression of the Ezh2 4A mutant
compromised the expression of Bim and protected TF1 cells
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from JNK inhibition-induced cell death compared to wild-type
Ezh2 expressing cells (Fig. 6h, i). Our findings demonstrate that
four threonine phosphorylation sites negatively regulate Ezh2
activity and are required for full interaction between Ezh2 and
smurf2 for its degradation. Thus, regulation of Cdk1 activity is a
key step in JNK-mediated modulation of Ezh2 function.
Cdk1 modulates Ezh2 and survival of erythroblasts. Next, we
questioned how JNK controls the activity of Cdk1. De-
phosphorylation of Tyr-15 is required for Cdk1 activation41.
Suppression of JNK by SP600125 or JNK1 knockdown sig-
nificantly reduced phosphorylation of Tyr-15 of Cdk1 in human
erythroblasts (Fig. 7a, b). Conversely, elevated Cdk1 Tyr-15
phosphorylation was observed in P38α−/− erythroblasts which
bear enhanced JNK activity compared with P38α+/− erythro-
blasts, implying that JNK modulates Cdk1 via Tyr-15 (Fig. 7c). To
address the role of Cdk1 in the regulation of erythroblast survival,
we silenced Cdk1 expression by a Cdk1-specific shRNA. This
resulted in increased expression of Ezh2 under both basal and
JNK inactivation conditions (Supplementary Fig. 8c and Fig. 7d).
Importantly, lack of Cdk1 compromised the transcription of Bim
and protected erythroblasts under JNK inactivation conditions
(Fig. 7e, f). These findings demonstrate that Cdk1 functions
downstream of JNK and bridges JNK activity to Ezh2 modula-
tion. Our results thus establish a critical signaling cascade
involving P38/JNK/Cdk1/Smurf2/Ezh2/Bim in controlling survi-
val of erythroblasts.
Discussion
Our work has uncovered a self-restraining function of P38α in
stress erythropoiesis by integrating apoptotic signals in erythro-
blasts during the recovery from anemia. Therefore, P38α acts as a
molecular brake to limit over-active erythropoiesis in response to
stress. Relief of this molecular brake by inhibiting P38 enhances
stress erythropoiesis and accelerates recovery from anemia, thus
providing a potential therapeutic strategy for treating patients
with anemia (Fig. 7g).
Both P38 and JNK belong to MAPK family. Our findings show
that in human primary erythroblasts, EPO-induced activation of
JNK only occurs briefly, whereas activation of P38 persists. The
intensity, duration, and fluctuation of stimulation of signaling
pathways are all critical in determining the eventual output to
affect cell fate decisions42. Endurance of activated signaling
pathways by EPO/EPOR is regulated by various mechanisms such
as availability of adaptor proteins, endocytosis of EPO/EPOR43,
expression of specific phosphatases, and cross-talk between
multiple downstream pathways of EPO/EPOR44. Adding to the
complexity, recent findings demonstrate that extracellular bind-
ing changes between EPO and EPOR due to EPO variant result in
selectively altered downstream signaling responses, which reveals
a mechanism in EPO/EPOR signaling modulation45.
Gene expression profiling did not reveal elevated expression of
other members of the P38 kinase family (P38β/γ/δ) in P38α−/−
erythroblasts. Since P38β can also be activated by MKK646, we
have performed q-PCR experiments and found that expression of
P38β in mouse erythroblasts was very low, which is in agreement
with previous findings in human erythroblasts47, suggesting that
P38β may not play an important role in regulation of ery-
thropoiesis. The expression of P38γ was even lower than P38β in
mice erythroblasts, although P38γ was found to express in human
erythroblasts47. Hence, other members of P38 family may not
compensate for the loss of P38α in mice erythroblasts, high-
lighting the importance of P38α in erythropoiesis.
We propose that the JNK/Ezh2 signaling serves as a pro-
survival mechanism in erythroblasts independent of EPO. Data
from us and others suggests that JNK activity is required for
maintaining P53 protein. Loss-of-MKK7 inhibits JNK activity,
accelerates P53 degradation, and promotes lung cancer develop-
ment48. In contrast, in hematopoietic system-derived malig-
nancies, like leukemia, which rarely bear mutations in P53
compared to solid tumors, JNK activity is required for leukemic
cells to survive22. Our findings that inhibition of JNK causes
apoptosis while promotes degradation of P53 in human ery-
throblasts, indicate that the consequence of JNK activation may
depend on whether P53 plays an essential role in regulating
apoptosis in specific cell types. Indeed, there is evidence to suggest
that P53-independent regulation of apoptosis via LRF/Bim, Fas/
FasL, and TRAIL exist in erythroid cells14,25,49. Our findings
show that Ezh2 is a downstream target of P38α/JNK pathways,
establishing a connection between critical P38α/JNK signals and
PRC2, an essential epigenetic regulator. Our results reveal a signal
transduction mechanism for sensing extracellular/intracellular
changes to chromatin re-modeling, which enables erythroblasts to
adapt to changing environment to maintain homeostasis.
Our findings demonstrate that Cdk1 functions downstream of
JNK to regulate Ezh2 stability and its activity. Phosphorylation of
four threonine sites in the middle domain of Ezh2 by Cdk1
mediates full interaction to bind to Smurf2 for its degradation.
We propose a two-step mechanism by which JNK regulates Ezh2
via Cdk1 in erythroblasts. If JNK inhibition is short-term, acti-
vated Cdk1 phosphorylates and decreases Ezh2 activity to trigger
target gene expression. However, if JNK inactivation persists,
endured activated Cdk1 mediates phosphorylation and degrada-
tion of Ezh2 via Smurf2 for a longer duration compromising Ezh2
function.
P38 has been reported to positively regulate P5350. However,
those results are mostly from cancer cell lines in which signal
transduction usually has been dysregulated. In contrast, we
observed enhanced P53 protein in P38α−/− erythroblasts,
Fig. 5 JNK inhibits Bim expression through suppressing Smurf2-mediated degradation of Ezh2. a mRNA (left) and protein (right) levels of Ezh2 in human
erythroblasts triggered by SP600125 assessed by q-PCR or immunoblotting. b Ezh2 protein level induced by JNK1 silencing measured by immunoblotting.
c Time course of Ezh2 levels in CHX-treated human erythroblasts with DMSO or SP600125. d SP600125-induced degradation of Ezh2 in the presence of
DMSO or MG132 (10 µM) by immunoblotting. e mRNA expression of HOXA9 in human erythroblasts induced by SP600125 (left) or JNK1 shRNA (right)
by q-PCR. f Quantitative chromatin immunoprecipitation analysis of occupancy of Ezh2 (left, n= 5) and H3K27me3 (right, n= 3) on Bim promoter in
human erythroblasts treated with vehicle or SP600125. g mRNA (left) and protein (right) levels of Bim induced by GSK126 (5 µM) for 12 h. h Apoptosis of
human erythroblasts trigged by GSK126 and measured by flow cytometry. i mRNA expression of Bim induced by Ezh2 silencing. j Representative flow
cytometry profile (left) and quantification (right) of apoptotic human erythroblasts induced by Ezh2-specific shRNA (n= 4). k Ezh2 protein levels in P38α
+/− and P38α−/− erythroblasts by immunoblotting. l mRNA levels of HOXA9 in P38α+/− and P38α−/− erythroblasts by q-PCR. m Apoptosis in P38α+/−
and P38α−/− erythroblasts subjected to GSK126 (5 µM) (n= 4). n Protein levels of Ezh2, Smurf2, and Bim in human erythroblasts transduced with control
or smurf2-specific shRNA then treated with SP600125. o Representative flow cytometry profile (left) and quantification (right) of SP600125-induced
apoptosis of human erythroblasts transduced with control or smurf2-specific shRNA (n= 3). Blots are representative of two independent experiments.
Data are shown as mean ± s.e.m. *P < 0.05 (two-tailed unpaired Student’s t-test)
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suggesting that P38α physiologically negatively modulates P53.
Recent studies show that P38 is a potential target for certain
cancer therapies51. Our findings that P38 regulates P53 and Ezh2
through JNK further provides insight into the role of P38 in
tumorigenesis (Fig. 7g). Given the fact that many anemias are
caused by chemotherapy, we propose an alternative therapeutic
strategy for improving the outlook in anemia patients through
inhibition of P38. Inhibition of P38 not only promotes ery-
thropoiesis by relief of self-restraint in erythroblasts but also
potentially maintains a higher level of P53 in cancer cells which is
doubly beneficial for cancer patients who bear wild-type P53.
Methods
Reagents and cell culture. P38 inhibitor SB203580, JNK inhibitor SP600125, Jak2
inhibitor II, and MG132 were purchased from EMD Bioscience. Cdk inhibitor
Roscovitine was purchased from Cell Signaling technology. Cycloheximide was
purchased from Sigma-Aldrich. Human Stem cell factor (SCF), thrombopoietin
(TPO), and FLT3-ligand (FLT3L), human GM-CSF, murine IL-3 and SCF were
purchased from Peprotech. EPO was manufactured by Amgen. Fetal bovine serum
(FBS) was purchased from Hyclone. TF1 human erythroid cells (American Type
Culture Collection (ATCC)) were cultured in RPMI 1640 medium supplemented
with 10% FBS and GM-CSF (2 ng ml−1) and 1% penicillin/streptomycin. HEK293T
(ATCC) and Hela cells (ATCC) were kept in DMEM supplemented with 10% FBS
and 1% penicillin/streptomycin. All cell lines were authenticated by supplier. All
cells were tested for mycoplasma contamination.
Mice and animal studies. Mice carrying the floxed P38α alleles (P38αfl/fl) was
kindly provided by Dr. Angel R. Nebreda6,13. P38αfl/fl mice were mated among
themselves and to Mx1-Cre mice (The Jackson Laboratory, Bar Harbor, ME) to
create Mx1-Cre/P38αfl/+ (P38α+/−) mice and Mx1-Cre/P38αfl/fl (P38α−/−) mice.
Genotypes were confirmed by PCR of tail DNA. To induce the expression of Cre to
delete floxed P38α alleles, 6- to 8-week-old male and female mice were injected
intraperitoneally with 300 µg PolyIC every other day for three times and mice
rested for 6 weeks prior to initiation of experiments, including gene analysis. All
studies were performed in a C57Bl/6 genetic background. Mice were randomized
based on weight. The investigators were not blinded for group allocations. All mice
were maintained in specific pathogen-free conditions, and experiments were
approved by the Institutional Animal Care and Use Committee (IACUC) of the
Indiana University School of medicine.
P38α+/− and P38α−/− mice were intraperitoneally injected with PHZ (100 mg
per kg body weight) once to induce hemolytic anemia. For induction of central
anemia, a single intraperitoneal injection of 5-fluorouracil (150 mg per kg body
weight) was utilized. To inhibit JNK, P38α+/− and P38α−/− mice were injected
daily intraperitoneally with SP600125 (40 mg per kg body weight). Peripheral blood
was collected from tail vein at indicated times and hematological parameters were
analyzed using a HEMAVET 950FS analyzer.
Administration of P38 inhibitor SB203580 to mice was performed52. In brief,
Mice were injected intraperitoneally with SB203580 (15 mg per kg body weight) or
vehicle every other day before (2 injections) and during PHZ challenge. Apoptosis
and cell cycle of BM erythroblast subsets was measured by flow cytometry.
For the transplantation experiment, 1 × 106 bone marrow cells from P38α+/−
and P38α−/− mice (CD45.2+) were isolated and injected into lethally irradiated
C57BL/6-CD45.1 recipient mice (CD45.1+CD45.2+) through tail vein. The donor
chimerism were monitored by flow cytometry analysis of peripheral blood samples
with anti-mouse CD45.1-PE (553776, BD Bioscience) and CD45.2-FITC antibodies
(553772, BD Bioscience) at a 1:50 dilution. After donor chimerism was stable over
90%, chimeric mice were subject to PHZ challenge.
Lentiviral transduction and erythroid differentiation. Purified human cord
blood CD34+ HSPCs were purchased from the Angio Biocore, IU Melvin and Bren
Simon Cancer center and cultured in SFEM serum-free expansion medium
(StemCell Technologies) supplemented with stem cell factor (SCF) (100 ng ml−1),
thrombopoietin (TPO) (100 ng ml−1), and FLT3-ligand (FLT3L) (100 ng ml−1).
For erythroid differentiation, CD34+ HSPCs were cultured in SFEM serum-free
medium containing SCF (40 ng ml−1) and erythropoietin (EPO) (0.5 Uml−1) for
around 5 days for further experiments. For generation of lentivirus, HEK293T cells
were transfected with the lentiviral constructs described below along with packa-
ging vectors using ProFection Mammalian Transfection System (E1200, Promega)
according to the manufacturer’s protocol. Supernatants containing viral particles
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were collected and filtered with 45 µM filter after 48 h of transfection. For lentiviral
transduction, CD34+ cells were infected with lentivirus after culturing for 24 h in
the presence of 8 µg ml−1 polybrene (Sigma-Aldrich) and spun at 800×g for 90 min
at room temperature.
Cytospin preparation. A total of 1–2 × 105 cells in 200 μls were used for cytospin
using the Thermo Scientific Shandon Cytospin 3 cytocentrifuge. The slides were
stained with May-Grünwald solution (Sigma-Aldrich) for 5 min, rinsed in deio-
nized water four times for each 30 s, and subsequently stained with Giemsa solu-
tion (Sigma-Aldrich) for 15 min. The images were taken using a Leica inverted
microscope.
Constructs. pRK-Myc-Smurf2(#13678) was provided by Dr Ying Zhang, pCS2-
Myc-Cyclin B1(#12176) by Dr Marc Kirschner, and pUHD-HA-CDK1(#27652) by
Grag Enders and purchased from Addgene (Cambridge, MA). To generate trun-
cated mutants, C2, WW2, and HECT domain of Smurf2 were cloned by PCR from
full-length Smurf2 and inserted into CMV-Myc vectors with the following primers
(5′–3′): C2 domain, forward, GAATTCGTCAAGCTGCGCCTGACAGTACTC,
reverse, AAGCTTTCAGTCTCTGGACTGAAGACTTACTACTATCTG; WW
domain, forward, GAATTCAACGATTTACCAGACGGCTGGGAA, reverse,
AAGCTTTCAGTTAGCAGACAGCCGAGGATCTGTAAATTG; HECT domain,
forward, GAATTCGCAGGTCATTGCCGCATTGAGGTTTCC, reverse,
AAGCTTTCATTCCACAGCAAATCCACATGTTTCTTC. The Flag tagged Ezh2
truncations were generated with the following primers (5′–3′): Ezh2-N (1–348),
ATGCGGCGCGCCGGCCAGACTGGGAAGAAATCTG, reverse, TACGT
TAATTAATCACTCAGCGGTGAGAGCAGCAGCAAAC; Ezh2-M (330–530),
ATGCGGCGCGCCTACCAGCATTTGGAGGGAGCAAAG, reverse, TACGT
TAATTAATCAATGATCACAGGGTTGATAGTTGTAAAC; Ezh2-C (523–751),
forward, ATGCGGCGCGCCTACAACTATCAACCCTGTGATCATC, reverse,
TACGTTAATTAATCAAGGGATTTCCATTTCTCTTTCG.
For knockdown experiments, shRNA sequences targeting human JunD (5′-CT
GGAGGATTTACACAAGCAGAACCAGCT-3′), JNK1(5′-GACTCAGAACACA
ACAAACTT-3′), Bim (5′-GACCGAGAAGGTAGACAATT-3′), Ezh2 (5′-TATGA
TGGTTAACGGTGATCA-3′), Smurf2 (5′-GATGAGAACACTCCAATTA-3′),
and CDK1 (5′-GGGGATTCAGAAATTGATC-3′) were cloned into pCL2 GFP
lentiviral vectors provided by Dr. Helmut Hanenberg. The shRNA sequence against
mouse Map3k4 (5′-TTACGTCATCTGGACTAAT-3′) was cloned into pMKO.1
GFP retroviral vector which was kindly provided by Dr. William Hahn and
purchased from Addgene (#10676).
Double, triple, and quadruple mutations of Ter350, Ter372, Ter419, and Ter492
within Ezh2-M domain into alanine were generated using Quikchange II site
directed mutagenesis kit (Agilent) with the following primers (5′–3′): T350A,
forward, GAGCGGATAAAGGCCCCACCAAAAC, reverse, GTTTTGGTGGGG
CCTTTATCCGCTC; T372A, forward, AGCAGGCCCAGCGCCCCCACCATTA,
reverse, TAATGGTGGGGGCGCTGGGCCTGCT; T419A, forward, TCTCGGTG
TCAAGCACCAATAAAGA, reverse, TCTTTATTGGTGCTTGACACCGAGA;
T492A, forward, GAGGATGTGGATGCTCCTCCAAGGA, reverse, TCCTTGG
AGGAGCATCCACATCCTC. The mutations were confirmed by sequencing. Wild
type full length Ezh2 and quadruple 4A mutant Ezh2 were cloned into puc2CL6
GFP lentiviral vectors provided by Dr. Helmut Hanenberg.
Flow cytometry analysis. For analyzing mice erythroblasts, BM cells from P38α
+/− and P38α−/− mice were collected and washed with staining buffer (PBS+ 5%
FBS). Then cells were subsequently stained for 30 min on ice with the following
anti-mouse antibodies at a 1:50 dilution:CD71-FITC (553266), Ter119-APC
(557909) or Ter119-PE (553673) from BD Biosciences. To evaluate human ery-
throid differentiation, collected and washed cells were incubated for 30 min on ice
with the following anti-human antibodies at a 1:50 dilution: CD235a-PE (12-9987-
82, eBioscience), CD71-PerCP/Cy5.5 (334114,Biolegend) or CD71-APC (334108,
Biolegend). After wash with staining buffer, the cell pellets were resuspended in
staining buffer supplemented with DAPI (Thermo Fisher Scientific) or Propidium
iodide (PI) (Sigma-Aldrich). All samples were measured with a BD LSR-II or FACS
Calibur (BD Biosciences) and analyzed with Flowjo (Treestar, Ashland, OR, USA).
Apoptosis and cell cycle analysis. Treated human erythroblasts or mice subset
erythroblasts were stained with indicated antibodies against surface markers as
described above. To evaluate apoptosis, cells were incubated with APC-conjugated
Annexin V (550475, BD Biosciences, 1:50) or PE-conjugated Annexin V (556422,
BD Biosciences, 1:50) for 10 min at room temperature in the dark. Then, DAPI or
Propidium iodide (PI) was added according to the instructions of the manu-
facturers. The samples were measured on a BD LSR-II (BD Biosciences) and
analyzed with Flowjo.
For cell cycle analysis, human erythroblasts or mice erythroblast subsets were
fixed and permeabilized using the BD Cytofix/Cytoperm Fixation/Permeabilization
Solution Kit (BD Biosciences) according to the manufacturer’s protocol. Cells were
then stained with Ki67 antibody (556027, BD Biosciences, 1:20). DAPI was then
added before analysis on a BD LSR-II.
Fluorescence-activated cell sorting. Briefly, bone marrow cell suspensions from
P38α+/− and P38α−/− mice were pre-treated with rat anti-mouse CD16/CD32
antibody (2.4G2, BD Biosciences), and subsequently stained with APC-conjugated
anti-mouse Ter119 (BD Biosciences,1:50) and FITC-conjugated anti-mouse CD71
(BD Biosciences,1:50) for 30 min in the dark at 4 °C. After wash, cells were stained
with Propidium iodide before sorted on BD SORP Aria (BD Biosciences).
Gene expression profiling analysis and bioinformatics analysis. P38α+/− and
P38α−/− mice were challenged with PHZ to induce anemia, on day 4 of recovery,
erythroblasts (CD71highTer119+) from three mice of each genotype were sorted
and sent to Miltenyi Biotec Inc (Auburn, CA). RNA was extracted, and gene
expression profiling was analyzed using Agilent Whole-Mouse Genome Oligo
Microarrays. Data preprocessing and discriminatory gene analysis was conducted
by Miltenyi Biotec Inc (Auburn, CA). Based on the log2-tramsformed normalized
intensity values, unpaired Student’s t-tests (two-tailed, equal variance) was applied
to evaluate differences between the means of P38α+/− and P38α−/− samples. A
correction for multiple testing of the t-test p-values was conducted using the
method of Benjamini and Hochberg. A p-value ≤0.05 was used as cutoff. The
statistical tests were complemented by a none-statistical quantification of the
median expression difference between the two groups. An effect size of 2 (i.e., a fold
change of ±2×) was chosen for the selection of candidate reporters.
The identified differentially expressed (DE) genes (fold change >1.5) were used
to conduct pathway analyses by Qiagen Ingenuity Pathway Analysis (IPA)
(Ingenuity Systems). To perform Gene set enrichment analysis (GSEA), pre-ranked
gene list was analyzed by GSEA software (Broad Institute of MIT and Harvard)
using the MSigDB gene sets.
Cell viability assays. Briefly, TF1 cells grown in 96-well plates were treated as
described. Then, 10 µL of MTT (5 mgml−1) was added to each well. The plate was
incubated at 37 °C for 2 h. Then, DMSO was added to each well and mix thor-
oughly with the pipette to dissolve the formazan. Absorbance of each sample was
read at 570 nm using a microplate reader (Molecular Devices). After substrate of
background control, cell viability was expressed as a ratio of absorbance relative to
that of control.
Immunoblotting. Collected cells were lysed in a lysis buffer (20 mM Tris (pH 7.5),
150 mM NaCl, 1 mM glycerolphosphate, 1 mM EDTA, 1 mM EGTA, 2.5 mM
sodium pyrophosphate, 1% Triton X-100, 1 mM Na3VO4, 1 µg ml−1 leupeptin
(Cell Signaling Technology). The supernatant were obtained by centrifugation at
10,000×g for 30 min at 4 °C. Protein concentration was quantified by Bicinchoninic
Acid (BCA) Protein Assay kit (Thermo Fisher Scientific). Cell lysates were heated
to 95–100 °C for 5 min in sample buffer (187.5 mM Tris-HCl, 6% w/v SDS, 30%
glycerol, 150 mM DTT, 0.03% w/v bromphenol blue), and an equal amount of
protein was loaded on precast SDS-PAGE (Thermo Fisher Scientific) in running
buffer and transferred to nitrocellulose membrane. The membrane was incubated
in blocking buffer (1X TBS/T with 5% w/v non-fat dry milk, and then incubated
with indicated antibodies according to the manufacturer’s instructions. The
Supersignal West Dura extended duration detection system (Thermo Fisher Sci-
entific) was used to expose the membrane to film. Antibodies against P38α
(9212,1:1000), phospho-P38 (9211, 1:1000), JNK1(3708, 1:1000), Total JNK (9252,
1:1000), phosphor-JNK (9251,1:1000), Ezh2 (5246, 1:3000), LRF (13097, 1:1000),
CDK1(28439, 1:1000), phosphor-CDK1(9111, 1:1000), P53 (2524, 1:1000), Myc tag
(2272, 1:1000), and phosphor-T-P (9391, 1:1000) are from Cell Signaling. Anti-P53
(sc-162, 1:1000), anti-Bim (sc-11425, 1:1000), anti-HA (sc-805, 1:1000) are from
Santa Cruz Biotechnology. Anti-Flag (T-7425, 1:2000) and anti-actin (A5316,
1:5000) are from Sigma-Aldrich. Anti-JunD (07-1334, 1:1000) and anti-H3K27me3
(07-449, 1:1000) is from Millipore. Original immunoblots are provided in Sup-
plementary Fig 9.
Retroviral production and transduction. Retroviral pMKO.1GFP vector con-
taining shRNA sequence against mouse Map3k4 was transfected into the Phoenix
packaging cell line using ProFection Mammalian Transfection System (E1200,
Promega). Supernatants were collected at 48 h post transfection and filtered with
0.45 µM filters. Freshly isolated BM cells were incubated in IMDM containing 20%
FBS, 1% penicillin/streptomycin and pre-stimulated with 100 ng ml−1 SCF and
10 ng ml−1 IL-3 for 48 h prior to retroviral infection on Retronectin (Takara). After
transduction for 48 h, GFP positive cells were sorted for further experiments.
Quantitative real-time PCR. For gene expression analysis, total RNA was
extracted using RNeasy Micro Kit (QIAGEN, MD) according to the manufacturer’s
protocol. cDNA was synthesized using SuperScript III reverse transcriptase
(Thermo Fisher Scientific). Real-time PCR analysis was performed using the SYBR
Green Master Mix (Sigma-Aldrich) following the manufacturer’s protocol on a
7500 Real-Time PCR system (Applied Biosystem). The relative expression of target
genes was calculated using the delta–delta Ct method and normalized to the β-actin
mRNA content. The Primer sequences are showed in Supplementary Tables 1
and 2.
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Immunoprecipitation and co-immunoprecipitation. Cultured HEK293T cells
were transfected or co-transfected with indicated plasmids for 48 h. After wash
with cold PBS, ice-cold cell lysis buffer (20 mM Tris pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerolphosphate, 1 mM Na3VO4, protease inhibitor mixture (Sigma-Aldrich) and
PMSF) were added to the cells for 30 min. After centrifuge, the supernatants were
collected. Pre-cleared lysates were incubated with anti-Flag beads (Sigma-Aldrich)
with gentle rocking overnight at 4 °C. Beads were washed three times with cell lysis
buffer and suspended in SDS protein loading buffer. The samples were heated to
95–100 °C for 5 min. Immunoprecipitation lysates were analyzed by western
blotting with indicated antibodies.
Chromatin immunoprecipitation (ChIP) assays. After treated with or without
Sp600125 (20 µM), human erythroblasts were subjected to the ChIP assay using the
EZ-ChIP kit (EMD Millipore) according to the manufacturer’s instructions. Briefly,
the cells were cross-linked for 10 min by addition of 37% formaldehyde to a final
concentration of 1% at room temperature. 20X glycine were added to quench
cross-link. After wash, cell pellets were suspended in SDS Lysis Buffer and soni-
cated to shear DNA. Collected supernatants were incubated with antibody for
overnight at 4 °C with rotation. After elution of protein/DNA complexes and
reversal of cross-link, the DNA was purified using spin columns and further
analyzed by quantitative PCR. The Primer sequences are showed in supplementary
table 3. The antibodies used for CHIP experiments are anti-H3K27me3 (07-449,
Millipore,1:500), anti-Ezh2 (5246, Cell Signaling, 1:100).
Statistical analysis. The animal sample sizes were estimated according to previous
studies performed in the similar experiments and the known variability of the
assays. The data distribution generally met the assumptions of the tests. All
quantitative data are presented as mean ± s.e.m. Two-tailed, unpaired Student’s t-
tests were performed. Result was considered significant if the P-value was below
0.05.
Data availability
Gene expression data have been deposited in the Gene Expression Omnibus (GEO)
database under the accession code GSE111751. The authors declare that all the other data
supporting the findings of this study are available within the article and its Supple-
mentary Information, or from the corresponding author upon reasonable request.
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